Cellular Therapies: A Canadian Blood Services Research and Development Symposium

Transfusion Medicine Reviews

Volumn 21, Issue 4, 2007, Pages 317-336

  Shehata, Nadine ^a,b,c   Lin, Yulia ^a,b,c   Pendergrast, Jacob ^a,b,c   Branch, Donald R ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ARTICLE; BLOOD BANK; BLOOD TRANSFUSION; CANADA; CELL THERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOGENETICS; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH SERVICES RESEARCH; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA; MARKET; MONONUCLEAR CELL; NATURAL KILLER CELL; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; STEM CELL GENE THERAPY;

BLOOD BANKS; BLOOD TRANSFUSION; CANADA; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELLS; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; MODELS, BIOLOGICAL; NEOPLASMS; RESEARCH; TISSUE THERAPY;

EID: 34548832240     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2007.05.007     Document Type: Article

References (70)

1. Barnes D.W., and Loutit J.F. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol 3 (1957) 241-252
2. Mathe G., Amiel J.L., Schwarzenberg L., et al. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 25 (1965) 1525-1531
3. Bortin M.M., Rimm A.A., and Saltzstein E.C. Graft versus leukemia: Quantification of adoptive immunotherapy in murine leukemia. Science 179 (1973) 811-813
4. Weiden P.L., Flournoy N., Sanders J.E., et al. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 13 (1981) 248-251
5. Kirkpatrick C.H., Rich R.R., Graw R.G., et al. Treatment of chronic moniliasis with lymphocyte transfusions. Lancet 2 (1970) 569 (letter)
6. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
7. Drobyski W.R., Keever C.A., Roth M.S., et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82 (1993) 2310-2318
8. Bar B.M., Schattenberg A., Mensink E.J., et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11 (1993) 513-519
9. Slavin S., Naparstek E., Nagler E., et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23 (1995) 1553-1562
10. Bollard C.M., Aguilar L., Straathof K.C., et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200 (2004) 1623-1633
11. Grimm E.A., Mazumder A., Zhang H.Z., et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155 (1982) 1823-1841
12. Rosenberg S.A., Spiess P., and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233 (1986) 1318-1321
13. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
14. Berzofsky J.A., Ahlers J.D., and Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1 (2001) 209-229
15. Blaese R.M., Culver K.W., Miller A.D., et al. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270 (1995) 475-480
16. Cairo M.S., and Wagner J.E. Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood 90 (1997) 4665-4678
17. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
18. Barker J.N., Davies S.M., DeFor T., et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: Results of a matched-pair analysis. Blood 97 (2001) 2957-2961
19. Eapen M., Rubinstein P., Zhang M.-J., et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 24 (2006) 145-151
20. Majhail N.S., Weisdorf D.J., Wagner J.E., et al. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 107 (2006) 3804-3807
21. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
22. Verneris M.R., Brunstein C., DeFor T.E., et al. Risk of relapse (REL) after umbilical cord blood transplantation (UCBT) in patients with acute leukemia: Marked reduction in recipients of two units. Blood 106 (2005) 93 (abstr)
23. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
24. Kiessling R., Klein E., and Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5 (1975) 112-117
25. Kiessling R., Klein E., Pross H., et al. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5 (1975) 117-121
26. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 (1985) 1485-1492
27. Kärre K., Ljunggren H.G., Piontek G., et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986) 675-678
28. Multhoff G., Botzler C., Jennen L., et al. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol 158 (1997) 4341-4350
29. Krause S.W., Gastpar R., Andreesen R., et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase I trial. Clin Cancer Res 10 (2004) 3699-3707
30. Gong J.H., Maki G., and Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8 (1994) 652-658
31. Arai S., Kindy K., Swearingen M., et al. Phase I study of adoptive immunotherapy using the cytotoxic natural killer (NK) cell line, NK-92, for treatment of advanced renal cell carcinoma and malignant melanoma. Blood 16 (2003) 102 (abstr)
32. Tonn T., Becker S., Esser R., et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10 (2001) 535-544
33. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 16 (2006) 412-418
34. Yodoi J., Teshigawara K., Nikaido T., et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol 134 (1985) 1623-1630
35. Nagata H., Konno A., Kimura N., et al. Characterization of novel natural killer (NK)-cell and gamma-delta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 97 (2001) 708-713
36. Matsuo Y., and Drexler H.G. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res 27 (2003) 935-945
37. Suck G., Branch D.R., Smyth M.J., et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 33 (2005) 1160-1171
38. Suck G., Branch D.R., and Keating A. Irradiated KHYG-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol 82 (2006) 355-361
39. Suck G., Branch D.R., Aravena P., et al. Constitutively polarized granules prime KHYG-1 NK cells. Int Immunol 18 (2006) 1347-1354
40. Djeu J.Y., Jiang K., and Wei S. A view to a kill: Signals triggering cytotoxicity. Clin Cancer Res 8 (2002) 636-640
41. Leger C.S., and Nevill T.J. Hematopoietic stem cell transplantation: A primer for the primary care physician. CMAJ 170 (2004) 1569-1577
42. Petersdorf E.W. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol 11 (2004) 386-391
43. Antin J.H. Stem cell transplantation-harnessing of graft-versus-malignancy. Curr Opin Hematol 10 (2003) 440-444
44. Baron F., and Sandmaier B.M. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 12 (2005) 435-443
45. Schattenberg A.V., and Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol 17 (2005) 617-621
46. Branch D.R., Gallagher M.T., Forman S.J., et al. Endogenous stem cell repopulation resulting in mixed hematopoietic chimerism following total body irradiation and marrow transplantation for acute leukemia. Transplantation 34 (1982) 226-228
47. Drexler C., and Wagner T. Blood group chimerism. Curr Opin Hematol 13 (2006) 484-489
48. Moise Jr. K.J. Umbilical cord stem cells. Obstet Gynecol 106 (2005) 1393-1407
49. Rogers S., Lowenthal A., Terheggen H.G., et al. Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an arginemic patient. J Exp Med 137 (1973) 1091-1096
50. Cline M. Gene therapy: Current status and future directions. Schweiz Med Wochenschr 116 (1986) 1459-1464
51. Shimotohno K., and Temin H.M. Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell 26 (1981) 67-77
52. Rosenberg S.A., Aebersold P., Cornetta K., et al. Gene transfer into humans-Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocyte modified by retroviral gene transduction. N Engl J Med 323 (1990) 570-578
53. Orkin S.H., Motulsky A.G., co-chairs: Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Bethesda, MD, National Institute of Health 1995. Available: http://www4.od.nih.gov/oba/rac/panelrep.pdf
54. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 286 (1999) 2244-2245
55. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
56. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
57. Yoshimitsu M., Sato T., Tao K., et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A 101 (2004) 16909-16914
58. Huston D.P. The biology of the immune system. JAMA 278 (1997) 1804-1814
59. Pandha H.S., John R.J., Hutchinson J., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: A phase I/II study. Br J Urol Int 94 (2004) 412-418
60. Barrou B., Benoit G., Ouldkaci M., et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53 (2004) 453-460
61. Heiser A., Coleman D., Dannull J., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL response against metastatic prostate tumours. J Clin Invest 109 (2002) 409-417
62. Morse M.A., Clay T.M., Hobeika A.C., et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 11 (2005) 3017-3024
63. Antonia S.J., Mirza N., Fricke I., et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12 (2006) 878-887
64. Medin J.A., Liang S.B., Hou J.W., et al. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther 12 (2005) 540-551
65. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
66. Ott M.G., Schmidt M., Schwarzwaelder K., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12 (2006) 401-409
67. Blaese R.M., Culver K.W., Chang L., et al. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. Hum Gene Ther 4 (1993) 521-527
68. Marshall E. FDA halts all gene therapy trials at Penn. Science 287 (2000) 565-567
69. Woods N.B., Bottero V., Schmidt M., et al. Gene therapy: Therapeutic gene causing lymphoma. Nature 440 (2006) 1123 (letter)
70. Institute of Medicine of the National Academies. Committee on establishing a national cord blood stem cell bank program. In: Meyer E.A., Hanna K., and Gebbie K. (Eds). Cord blood: Establishing a national hematopoietic stem cell bank program (2005), The National Academies Press, Washington, DC. http://www.nap.edu/catalog/11269.html Available at http://www.nap.edu/catalog/11269.html